Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Myeloid, Acute 13Myelodysplastic Syndromes 6Myeloproliferative Disorders 3Leukemia, Myelomonocytic, Chronic 3Advanced Solid Tumour 3Small Cell Lung Carcinoma 2Recurrence 2Multiple Myeloma 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Advanced Breast Cancer 2Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neuroma 1Neoplasms 1Neoplasm Metastasis 1Multiple Sclerosis 1Lung Neoplasms 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Leukemia, Biphenotypic, Acute 1Idiopathic Pulmonary Fibrosis 1Esophageal Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Depression 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Blast Crisis 1

Interventions

toripalimab 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Lung Cancer × Injections × 30 days × Clear all
NCT07309276 2026-05-18

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 2 Recruiting
864 enrolled
Thoracic

Advanced Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡